Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results
Date:2/3/2009

ducts that treat urinary incontinence. In addition, the January 2009 issue of the Journal of Urology highlighted results from a clinical study of Macroplastique. The study concluded that in the Macroplastique patient group, the dry/cure rate was 36.9% versus 24.8% in the control patient group. The authors of the study concluded that Macroplastique is a safe, effective, minimally invasive material that can be administered on an outpatient basis. The combination of these factors resulted in record sales for Macroplastique in our fiscal third quarter," concluded Mr. Kaysen.

Fiscal Third Quarter and Nine Month Results for the Periods Ended December 31, 2008

Net sales for the three months ended December 31, 2008 were $3.4 million versus $3.7 million for the same period a year ago. Net sales for the nine months ended December 31, 2008 were $11.8 million, up 22% from $9.7 million for the same period a year ago.

Sales to customers in the U.S. for the three months ended December 31, 2008 were $1.9 million, down one percent, compared with $2.0 million in the same period a year ago. This decrease was due to the reimbursement uncertainty that has developed in the U.S. market for Urgent PC treatments. Sales to customers outside of the U.S. for the three months ended December 31, 2008 were $1.4 million, down 18% from $1.8 million in the year ago period. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales to customers outside of the U.S. declined approximately 5%.

Nine month sales to customers in the U.S. were $6.4 million, an increase of 52% from $4.2 million for the same period last year. Nine month sales to customers outside of the U.S. were flat at $5.5 million as compared with the same period last year. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales to customers outside of the U.S. declined approximately 2%
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 26, 2015 Research ... of the "Global Breast Cancer Monoclonal Antibodies ... Globally, Roche seems to dominate the ... inventory. Its block buster molecule, Herceptin has been ... It was found that breast cancer cells become ...
(Date:5/27/2015)... Fla. (PRWEB) May 27, 2015 Expanding ... dental cement manufacturer Avalon Biomed Inc. recently ... of Mokuda Dental Co. Ltd. , the largest ... inroad into the international market for Avalon Biomed, which ... Plus®, award-winning tricalcium silicate-based dental cements that have won ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2
... , SAN DIEGO , INDIANAPOLIS and WALTHAM, Mass. ... AMLN ), Eli Lilly and Company (NYSE: LLY ) and ... and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable ... Prescription Drug User Fee Act (PDUFA) action date of October 22, ...
... , May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... and Drug Administration (FDA), orphan-drug designation for AEZS-108, its ... cancer. AEZS-108 is currently in a Phase 2 trial ...
... Belgium and LUND, Sweden , May 6, 2010 , ... - TB-402 Demonstrates Superior Antithrombotic ... ThromboGenics ... from,their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant,that is ...
Cached Biology Technology:BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 3BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 4BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 5BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 6BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 7BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 8Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 2ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 3ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 4ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 5ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 6ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) 7
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... life forms that have been around since the dinosaurs, ... because they can simultaneously produce other valuable products ... Engineers at Oregon State University concede that such ... not science fiction many of the needed advances ...
... tested a new technique to ensure fresh produce is free ... particles created when gases are excited by an energy source. ... research shows, some can hide from its effects in the ... and vegetables is promoted as part of a healthy lifestyle, ...
... National Heart, Lung, and Blood Institute, part of the ... to Albert Einstein College of Medicine ... study of hemoglobin toxicity that may complicate blood transfusions ... goals include making blood transfusions safer and more effective ...
Cached Biology News:Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Assessing a new technique for ensuring fresh produce remains Salmonella-free 2Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin 2
... EZ-Spread Plating Beads Sterile plating in ... glass rods and potentially hazardous ethanol flaming, ... choices of ready-to-use sterile packaging: dispenser bottle for ... plating, Fastest and easiest way to ...
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
... IgY) , After we receive your antigen (see ... appropriate number of chickens and begin to collect ... (usually over a period of 3-5 days), we ... of four injections into the breast muscle. The ...
Biology Products: